Q-omics provides the consensus-scored PEX7 profile across patient tissues and cancer cell-line models. PEX7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PEX7 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PEX7 RNA expression shows 18,008 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where PEX7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PEX7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PEX7 survival associations across molecular data types. PEX7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PEX7 RNA expression–survival associations across cancer types. High PEX7 expression shows unfavorable associations in DLBC, LUAD and HNSC, but favorable associations in KIRC, LGG and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PEX7 RNA expression.
This table summarizes PEX7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PEX7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PEX7 shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in BRCA, BLCA and COAD. The KIRC box plot shows higher PEX7 RNA expression in normal versus tumor tissue (log2 FC = −0.930, t-test p < 0.001).
This table shows molecular features associated with PEX7 in patient tissues and cancer cell lines. In patient samples, PEX7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PEX7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
